TickerTalks
Browse all tickers →
TickerTalks›$RARE
RARARE

Ultragenyx Pharmaceutical Inc.

$RARE·$1.4B·Biotechnology·Healthcare
$15.07+3.6%YTD-34.7%1Y-56.2%
Price updated 3m ago·X counts updated 9d ago
RARARE
$RAREUltragenyx Pharmaceutical Inc.
$15.07+3.65%438 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $RARE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

438X posts · last 7 days
Oct 2Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $RARE's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Mixed sentimentAI analysisGenerated by AI from underlying data28 posts analyzed · as of 2026-10-02

The $RARE feed is almost entirely the SuperRare crypto token and the SuperRare NFT marketplace — not Ultragenyx the biotech. The conversation is a flat split between short setups (0.0225 stop 0.02389) and long/breakout calls off a 99.72% drawdown from ATH, with a Binance Monitoring Tag used as the pump catalyst. NFT sellers posting their 0.1-0.75 ETH clears round out the thread. No coherent directional thesis emerges.

Read what X is saying about $RARE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $RARE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-10-02

Falling on heavy selling — points lower unless it turns around.

Rare-disease pharma just lost its biggest trial — the FDA approval is nice, but the Angelman failure changed the story.

Ultragenyx develops gene therapies and small molecules for ultra-rare pediatric diseases. The stock sits at the literal bottom of its 52-week range after the Phase 3 Aspire trial for apazunersen (GTX-102) in Angelman syndrome failed its primary endpoint — a core pipeline asset gone.

  • The business is still growing: revenue grew 28.5% YoY to $214M last quarter on 83% gross margin, and the Sep 17 FDA approval for FAYUVI (rebisufligene etisparvovec) in pediatric MPS IIIA — the first-ever approved treatment — adds a new revenue stream, though commercial ramp from a tiny patient population takes years.
  • The Angelman failure is the real signal: GTX-102 was one of three major pipeline assets, and a Phase 3 miss on primary endpoint typically ends the development path; securities class actions (Pomerantz) have already been filed around the disclosure.
  • At -74% operating margin and $214M quarterly revenue against a $1.4B market cap, this is now a sum-of-approved-products value trade (FAYUVI + crysvita royalties + metabolic franchise) — not the pipeline multi-bagger it was.

Breaking-down holds unless Nov 3 earnings reset expectations with a credible FAYUVI launch trajectory and detail on the DTX401 (glycogen storage disease) Phase 3 timeline. A soft FAYUVI launch, or further pipeline news flow going the wrong way, confirms the de-rating toward the $10 single-digits.

What to watch: Nov 3 earnings — FAYUVI launch trajectory, crysvita royalty growth, and any update on DTX401 Phase 3 timeline. A FAYUVI miss or further pipeline attrition confirms the breaking-down tape; a strong launch could at least stabilize the stock.

On the calendar: 2026-11-03 — Q3 FY26 earnings

Read the AI verdict on $RARE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Rare disease biotech with approved drugs for fatty acid oxidation disorders and X-linked hypophosphatemia, plus a pipeline targeting lysosomal storage diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RARE.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $RARE

Neutral — Rare disease biotech with approved drugs for fatty acid oxidation disorders and X-linked hypophosphatemia, plus a pipeline targeting lysosomal storage diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-53.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-73.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-18.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
392%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
83.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-4.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.90$-1.22+26.2%
Q1 2026May 5, 2026$-1.84$-1.49-23.7%
Q4 2025Feb 12, 2026$-1.29$-1.20-7.5%
Q3 2025Nov 4, 2025$-1.81$-1.23-47.2%
Next earningsTue, Nov 3·consensus EPS $-1.11

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$214.0M+28.5%84.1%-35.0%$-0.90$-98.0M
Q1 FY26$136.0M-2.4%77.9%-124%$-1.84$-198.0M
Q4 FY25$207.0M+25.5%86.0%-55.1%$-1.29$-100.8M
Q3 FY25$159.9M+14.7%82.5%-107%$-1.81$-92.7M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$755.4M$295.2M – $3.0B-$4.60-$6.10 – -$1.3814
FY27$989.3M$773.4M – $1.5B-$0.69-$12.50 – $23.7414
FY28$1.1B$907.3M – $1.7B$0.22-$1.97 – $1.8514
FY29$1.3B$916.1M – $2.7B$1.15$0.72 – $2.838
FY30$1.6B$1.1B – $3.3B$2.94$1.84 – $7.1912

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-19.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-35.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 94.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 15Howard HornCFO7.1K sh$108KSellSep 15Huizenga Theodore AlanSVP, Chief Accounting Officer1.3K sh$17KSellSep 3Huizenga Theodore AlanSVP, Chief Accounting Officer161 sh$2KSellAug 3Parschauer Karah HerdmanEVP and Chief Legal Officer1.9K sh$47KSellAug 3Howard HornCFO4.7K sh$117KSellJul 1Howard HornCFO4.7K sh$156KSellJun 15Sanders Corazon (corsee) D.Director2.0K sh$50KSellJun 15Parschauer Karah HerdmanEVP and Chief Legal Officer1.9K sh$47KSellJun 1Howard HornCFO4.7K sh$111KSellMay 18Shehnaaz SulimanDirector5.7K sh$144K
1–10 of 12
+ 7 other (7 awards) in window

See when $RARE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementOct 148-K — Item 1.01: Material agreement
8-KMaterial agreementOct 78-K — Item 1.01: Material agreement
8-KOfficer or director changeMay 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 18 other (8 13Gs · 4 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Weekzacks.com·5d agoCan RARE's Approved Product Portfolio Drive Its Next Growth Phase?zacks.com·6d agoUltragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Millionglobenewswire.com·6d agoRep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)defenseworld.net·6d agoAnalyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)defenseworld.net·8d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport